Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses
Source abstract
Abstract
The induction of secretory IgA (sIgA) on mucosal surfaces is crucial for developing vaccines that effectively prevent Human immunodeficiency virus type 1 (HIV-1) transmission. However, the mucosal barrier significantly limits antigen absorption, resulting in weak systemic and mucosal immune responses. In this study, a novel dual-function nanovaccine for intranasal administration of HIV-1 native-like envelope (Env) proteins was developed. Specifically, the amphiphilic polymer coating (DPPD2) was synthesized by conjugating P-D2, a peptide that targets the CD11c receptor on dendritic cells (DCs), to DSPE-PEG (DP). DPPD2 was then employed to surface-functionalize the amino-modified mesoporous silica nanoparticle (MSN) that was loaded with Env and Toll-like receptor 9 agonist CpG, resulting in a DC-targeting nanovaccine. DPPD2/Env/CpG@MSN could synergistically boost trans-mucosal penetration of Env proteins and the recruitment, antigen uptake and activation of submucosal DCs. More importantly, we found that DPPD2/Env/CpG@MSN promoted germinal center (GC) responses in the muco-associated lymphoid tissue and draining lymph nodes, further leading to significantly enhanced HIV-1-specific sIgA antibody levels in situ and distant mucosal sites. Furthermore, systemic immune responses such as serum neutralizing antibodies against heterologous HIV-1 pseudoviruses and systemic T cell immunity were improved. Our study introduces a unique functional intranasal nanovaccine, providing a basis for developing subunit vaccines against mucosal viral infections. STATEMENT OF SIGNIFICANCE: The development of effective strategies to prevent mucosal transmission of HIV-1 is crucial for combating AIDS. Current HIV-1 Env subunit vaccines have shown limited immunogenicity in mucosal immunity studies. This work developed an intranasal nanovaccine, DPPD2/Env/CpG@MSN, to synergistically enhance trans-mucosal penetration of the Env protein and its subsequent uptake by submucosal DCs. The results demonstrated that DPPD2/Env/CpG@MSN effectively boosted germinal center responses and antibody production. The levels of Env-specific sIgA antibodies were significantly elevated in both local and distant mucosal sites. Moreover, the nanovaccine also elicited robust Env-specific T cell immune responses in spleen. This design provides a promising strategy for enhancing the immunogenicity of HIV-1 subunit vaccines in mucosal vaccination.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: HIV Research and Treatment · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Surface-functionalized silica-coated calcium phosphate nanoparticles efficiently deliver DNA-based HIV-1 trimeric envelope vaccines against HIV-110.1021/acsami.1c16989 ↗
2. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies10.1038/s41577-022-00753-w ↗
3. HIV-1 env trimers asymmetrically engage CD4 receptors in membranes10.1038/s41586-023-06762-6 ↗
4. Antibodies in HIV-1 vaccine development and therapy10.1126/science.1241144 ↗
5. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques10.1084/jem.183.1.215 ↗
6. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection10.1126/science.280.5362.427 ↗
7. Mucosal immunity: induction, dissemination, and effector functions10.1111/j.1365-3083.2009.02319.x ↗
8. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity10.1126/scitranslmed.abn1413 ↗
9. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings10.1016/j.hlife.2025.05.001 ↗
10. An HIV-1 vaccine based on bacterium-like particles elicits env-specific mucosal immune responses10.1016/j.imlet.2020.03.002 ↗
11. Vaccine with bacterium-like particles displaying HIV-1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques10.1111/1751-7915.14022 ↗
12. Mucosal vaccine adjuvants update
13. Biomaterial approaches for understanding and overcoming immunological barriers to effective oral vaccinations10.1002/adfm.201907170 ↗
14. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses10.1016/j.actbio.2017.10.019 ↗
15. Transmucosal delivery of nasal nanovaccines enhancing mucosal and systemic immunity10.1021/acs.nanolett.3c03419 ↗
16. Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles10.1021/acsami.8b18107 ↗
17. Bilayer-functionalized mesoporous silica nanoparticles for overcoming multiple barriers of mucus clearance, intestinal epithelium and P-glycoprotein efflux10.1016/j.matdes.2024.112820 ↗
18. The Nano–Intestine interaction: understanding the location-oriented effects of engineered nanomaterials in the Intestine10.1002/smll.201907665 ↗
19. Competitive success10.1038/nri713 ↗
20. Dendritic cells and the control of immunity10.1038/32588 ↗
21. A comprehensive understanding of the gut mucosal immune system in allergic inflammation10.1016/j.alit.2018.09.004 ↗
22. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors10.1089/153685903321538026 ↗
23. VEGF therapy: risky business for established plaques?10.1182/blood-2006-10-050856 ↗
24. Specialized lectures (SL)10.1046/j.1432-1033.270.s1.6.x ↗
25. Microparticle surface modifications targeting dendritic cells for non-activating applications10.1016/j.biomaterials.2012.06.049 ↗
26. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis10.1182/blood-2003-08-2729 ↗
27. Structures and immune recognition of Env trimers from two Asia prevalent HIV-1 CRFs10.1038/s41467-023-40321-x ↗
28. HIV-1 vaccine design through minimizing envelope metastability10.1126/sciadv.aau6769 ↗
29. Periodic mesoporous organosilica as a nanoadjuvant for subunit vaccines elicits potent antigen-specific germinal center responses by activating naive B cells10.1021/acsnano.3c00991 ↗
30. Innate antiviral immune signaling, viral evasion and modulation by HIV-110.1016/j.jmb.2013.12.003 ↗
31. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles10.1038/ncomms12041 ↗
32. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties10.1016/j.addr.2017.10.001 ↗
33. Lactoferrin-modified PLGA nanoparticles for pregabalin: development, characterization, in vitro targeting and pharmacodynamic evaluation10.1007/s13346-025-01848-2 ↗
34. Mucosal vaccines — Fortifying the frontiers10.1038/s41577-021-00583-2 ↗
35. Function of mucosa-associated lymphoid tissue in antibody formation10.3109/08820131003680369 ↗
36. Thymic function in MHC class II–deficient patients10.1016/j.jaci.2012.10.040 ↗
37. Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine10.1016/j.jconrel.2022.04.036 ↗
38. Mucosal vaccination for influenza protection enhanced by catalytic Immune-adjuvant10.1002/advs.202000771 ↗
39. CpG oligodeoxynucleotides facilitate delivery of whole inactivated H9N2 influenza virus via transepithelial dendrites of dendritic cells in Nasal Mucosa10.1128/JVI.00296-15 ↗
40. CCR7 acts as both a sensor and a sink for CCL19 to coordinate collective leukocyte migration10.1126/sciimmunol.adc9584 ↗
41. Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue10.1093/intimm/dxad045 ↗
42. The role of Th17 cytokines in primary mucosal immunity10.1016/j.cytogfr.2010.11.002 ↗
43. IL-17-dependent SIgA-mediated protection against nasal bordetella pertussis infection by live attenuated BPZE1 vaccine10.1038/s41385-018-0073-9 ↗
44. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa10.1038/mi.2009.100 ↗
45. Are anti-HIV IgAs good guys or bad guys?10.1186/s12977-014-0109-5 ↗
46. Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 Vector Prime, env protein boost immunizations in Rhesus monkeys
47. HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge10.1038/s41467-019-08739-4 ↗
48. Chiral Nanosilica drug delivery systems stereoselectively interacted with the intestinal mucosa to improve the oral adsorption of insoluble drugs10.1021/acsnano.2c10818 ↗
49. Nanodelivery strategies modulating tumor stromal cells for reverting the immunosuppressive tumor microenvironment10.1016/j.cclet.2025.112036 ↗
50. Nanoparticles exhibiting virus-mimic surface topology for enhanced oral delivery10.1038/s41467-023-43465-y ↗
51. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse10.1016/j.jconrel.2014.10.026 ↗
52. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability10.1016/j.immuni.2019.10.008 ↗
53. Germinal center B cell dynamics10.1016/j.immuni.2016.09.001 ↗
54. Periodic mesoporous organosilica-loaded mincle agonists enhance the immunogenicity of COVID-19 subunit vaccines by dual activation of B cells and dendritic cells10.1016/j.actbio.2024.12.056 ↗
55. T follicular helper cell heterogeneity: time, space, and function10.1111/imr.12740 ↗
56. Recent progress in mucosal vaccine development: potential and limitations10.1038/nri3251 ↗
57. Nasal vaccines for respiratory infections10.1038/s41586-025-08910-6 ↗
58. Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses10.1038/mi.2016.28 ↗
59. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy10.1016/j.jconrel.2024.07.056 ↗
60. NK cell membrane/MnO2 hybrid nanoparticle-adjuvanted intranasal vaccines synergistically boost protective immunity against H1N1 influenza infection10.1016/j.cej.2024.157381 ↗